US case analysis: Myriad at the Supreme Court

Managing IP Correspondent

August 31 2013

The subject of gene patentability is one of the most controversial topics in life sciences. In June 2013, the US Supreme Court reached a unanimous decision in the Association for Molecular Pathology v Myriad Genetics. It stated that companies cannot patent parts of naturally occurring human genes. Managing IP sat down with Fitzpatrick Cella Harper & Scinto attorneys Robert Fischer, John Carlin and Joshua Rothman to discuss the ruling

Unlock this content.

The content you are trying to view is exclusive to our subscribers.

To unlock this content:

Request Access or Login

Topics

Features MIP Special Focus Life Sciences 2013 (August 2013)

Managing IP Correspondent

more from across site and SHARED ros bottom lb

More from across our site

Trademarks

‘Lead before you feel ready’: Morgan Lewis lawyer marks 30 years

Anita Polott, who is celebrating three decades at Morgan Lewis this year, reflects on career progression, stepping into unfamiliar territory, and leadership frameworks

Sanjana Mishra, September 18 2026

Trademarks

Weekly take: Is the standalone IP practice losing its edge?

Technical excellence remains essential, but many firms are discovering that packaging IP with complementary practice areas can unlock new clients and a stronger competitive position

Sukanya Sarkar, September 18 2026

Patents

Rajah & Tann at 50: How Singapore gateway is driving global IP work

As international interest in Southeast Asia grows, Sheng Rong Tng discusses how changing client demands and the firm’s multidisciplinary model are helping it compete for complex regional mandates

Sukanya Sarkar, September 17 2026

Patents

How orbital AI, biotechnology, and manufacturing may test existing patent law limits

Todd Hopfinger, director in Sterne Kessler’s electronics practice group, says IP owners are contemplating how patent rights will be enforced as commercial activity expands beyond Earth

Todd Hopfinger, September 17 2026

Patents

Exclusive: Carpmaels boosts patent litigation firepower with Freshfields hire

Christopher Stothers' arrival strengthens the firm's life sciences, technology and UPC offering as competition for top European litigators intensifies

Max Walters, September 17 2026

Patents

Not ‘that’ kind of lawyer: patent attorney shares career experience

Armstrong Teasdale’s Jim Heinen Jr discusses the challenge of balancing billables, business development and family life and explains why not all patent lawyers are science nerds

September 15 2026

Patents

3d,Rendering.,Neon,Number,Five.,Glowing,Colorful,Line,Inside,The

The UPC's next chapter: five trends likely to shape European patent litigation into 2030

From cross-border jurisdiction to the end of the transitional period, Powell Gilbert’s Ioana Sabau and Bryce Matthewson predict the biggest talking points ahead

Ioana Sabau, September 15 2026

Patents

Texas,Flag,Blowing,In,The,Wind,In,Field,Of,Bluebonnet

Beyond the headlines: Texas growth is no longer just a litigation play

A wave of office launches and lateral hires reflects the draw of patent disputes, but booming AI, semiconductor and data centre markets are offering an even bigger IP opportunity

Sanjana Mishra, September 14 2026

Patents

Exclusive: Simmons associate loss leaves patent prosecution team bare

The hire of Frederick Nicolle as a partner continues Pinsent Masons' expansion while reducing Simmons’ patent prosecution offering in London to zero

Max Walters, September 14 2026

Patents

Exclusive: ABG IP bets on regional innovation hubs with fifth Spain office

The expansion into Granada forms part of a national ‘decentralisation’ strategy focused on providing proximity to research and tech businesses away from traditional hubs

Max Walters, September 14 2026